APA (7th ed.) Citation

Mai, E. K., Miah, K., Bertsch, U., Dürig, J., Scheid, C., Weisel, K., . . . Goldschmidt, H. (2021). Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age. Leukemia, 35(3), . https://doi.org/10.1038/s41375-020-0976-9

Chicago Style (17th ed.) Citation

Mai, Elias K., et al. "Bortezomib-based Induction, High-dose Melphalan and Lenalidomide Maintenance in Myeloma Up to 70 Years of Age." Leukemia 35, no. 3 (2021). https://doi.org/10.1038/s41375-020-0976-9.

MLA (9th ed.) Citation

Mai, Elias K., et al. "Bortezomib-based Induction, High-dose Melphalan and Lenalidomide Maintenance in Myeloma Up to 70 Years of Age." Leukemia, vol. 35, no. 3, 2021, https://doi.org/10.1038/s41375-020-0976-9.